Illicit drug breath profiling
Scientists from the Karolinska Institute (Stockholm, Sweden) have taken a step closer towards the development of portable illicit drug testing using exhaled breath.1 The study published in the Journal of Breath Research details the use of liquid chromatography?mass spectrometry (LC-MS) to analyse exhaled breath of patients recovering from acute drug abuse.
Scientists from the Karolinska Institute (Stockholm, Sweden) have taken a step closer towards the development ofportable illicit drug testing using exhaled breath.1 The study published in the Journal of Breath Research details theuse of liquid chromatography–mass spectrometry (LC–MS) to analyse exhaled breath of patients recovering from acutedrug abuse. This opens up the possibilities of roadside, criminal justice, clinical, and workplace drug abuse testing.
Lead author Olof Beck told The Column that the main aim of the investigation was to build on previous studiesto obtain good detectability for a broad range of drugs. His frustration with working with saliva and the associated analytical problems led him to try and use exhaled breath. Beck said: “People always asked me why is drug testing notas easy as alcohol testing (by breath). We decided to try it and were lucky.”
Currently, urine and blood are most commonly sampled to test for the abuse of illegal drugs. This can be invasive,uncomfortable, and a long analysis process. In addition, it is sometimes impossible in some situations; for example, onthe roadside. The challenge of using exhaled breath samples lay in collecting aerosol particles selectively with sufficientsensitivity, according to Beck.
The exhaled breath samples were collected from a group of 47 patients using a specially designed commericallyavailable mask. The mask had a specific filter to trap non-volatile microparticles that carry narcotic molecules.The molecules were then analysed by LC–MS that had been optimized for maximum sensitivity. The specificcompounds that were tested for were methadone, amphetamine, methamphetamine, 6-acetylmorphine, morphine,benzoylecgonine, cocaine, diazepam, oxazepam, alprazolam, buprenorphine, and tetrahydrocannabinol. The resultswere compared with analysis of urine and plasma samples to validate the method.
Beck told The Column that in the future the research group will work towardsdeveloping MS sensitivity for the very low level of aerosols available for analysis,as well as improving detection times.
Reference
1. O. Beck et al., Journal of Breath Research, DOI: 10.1088/1752-7155/7/2/026006 (2013).
This story originally appeared in The Column. Click here to view that issue.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
